TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy

Human Molecular Genetics

Volumn 24, Issue 7, 2014, Pages 2035-2048

  Yadava, Ramesh S ^a   Foff, Erin P ^a   Yu, Qing ^a   Gladman, Jordan T ^a   Kim, Yun K ^a   Bhatt, Kirti S ^b   Thornton, Charles A ^b   Zheng, Timothy S ^c   Mahadevan, Mani S ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c BIOGEN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FIBROBLAST GROWTH FACTOR 14; FIBROBLAST GROWTH FACTOR INDUCIBLE 14; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; RNA; UNCLASSIFIED DRUG; ANTIBODY; TNFSF12 PROTEIN, HUMAN; TNFSF12 PROTEIN, MOUSE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; TWEAK RECEPTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; GENE DELETION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MOUSE; MUSCLE FUNCTION; MYOTONIC DYSTROPHY; NONHUMAN; PRIORITY JOURNAL; PROTEIN TARGETING; SIGNAL TRANSDUCTION; SKELETAL MUSCLE; ADULT; ANIMAL; ANTAGONISTS AND INHIBITORS; DISEASE MODEL; DRUG EFFECTS; FEMALE; GENETICS; KNOCKOUT MOUSE; MALE; METABOLISM; MIDDLE AGED;

MUS;

ADULT; ANIMALS; ANTIBODIES; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MALE; MICE; MICE, KNOCKOUT; MIDDLE AGED; MYOTONIC DYSTROPHY; NF-KAPPA B; RECEPTORS, TUMOR NECROSIS FACTOR; SIGNAL TRANSDUCTION; TUMOR NECROSIS FACTORS;

EID: 84926460724     PISSN: 09646906     EISSN: 14602083     Source Type: Journal    
DOI: 10.1093/hmg/ddu617     Document Type: Article

References (47)

1. Turner, C. and Hilton-Jones, D. (2010) The myotonic dystrophies: diagnosis and management. J. Neurol. Neurosurg. Psychiatry, 81, 358-367.
2. Amack, J.D., Paguio, A.P. and Mahadevan, M.S. (1999) Cis and trans effects of the myotonic dystrophy (DM) mutation in a cell culture model. Hum. Mol. Genet., 8, 1975-1984.
3. Mahadevan, M., Tsilfidis, C., Sabourin, L., Shutler, G., Amemiya, C., Jansen, G., Neville, C., Narang, M., Barcelo, J., O'Hoy, K. et al. (1992) Myotonic dystrophy mutation: an unstable CTG repeat in the 3′ untranslated region of the gene. Science, 255, 1253-1255.
4. Taneja, K.L., McCurrach, M., Schalling, M., Housman, D. and Singer, R.H. (1995) Foci of trinucleotide repeat transcripts in nuclei of myotonic dystrophy cells and tissues. J. Cell Biol., 128, 995-1002.
5. Mahadevan, M.S., Yadava, R.S., Yu, Q., Balijepalli, S., Frenzel-McCardell, C.D., Bourne, T.D. and Phillips, L.H. (2006) Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat. Genet., 38, 1066-1070.
6. Mankodi, A., Logigian, E., Callahan, L., McClain, C., White, R., Henderson, D., Krym, M. and Thornton, C.A. (2000) Myotonic dystrophy in transgenic mice expressing an expanded CUG repeat. Science, 289, 1769-1773.
7. Echeverria, G.V. and Cooper, T.A. (2012) RNA-binding proteins in microsatellite expansion disorders: mediators of RNA toxicity. Brain Res., 1462, 100-111.
8. Childs-Disney, J.L., Hoskins, J., Rzuczek, S.G., Thornton, C.A. and Disney, M.D. (2012) Rationally designed small molecules targeting the RNA that causes myotonic dystrophy type 1 are potently bioactive. ACS Chem. Biol., 7, 856-862.
9. Warf, M.B., Nakamori, M., Matthys, C.M., Thornton, C.A. and Berglund, J.A. (2009) Pentamidine reverses the splicing defects associated with myotonic dystrophy. Proc. Natl. Acad. Sci. U S A, 106, 18551-18556.
10. Wheeler, T.M., Leger, A.J., Pandey, S.K., MacLeod, A.R., Nakamori, M., Cheng, S.H., Wentworth, B.M., Bennett, C.F. and Thornton, C.A. (2012) Targeting nuclear RNA for in vivo correction of myotonic dystrophy. Nature, 488, 111-115.
11. Jones, K.,Wei, C., Iakova, P., Bugiardini, E., Schneider-Gold, C., Meola, G., Woodgett, J., Killian, J., Timchenko, N.A. and Timchenko, L.T. (2012) GSK3beta mediates muscle pathology in myotonic dystrophy. J. Clin. Invest., 122, 4461-4472.
12. Mahadevan, M.S. (2012) Myotonic dystrophy: is a narrow focus obscuring the rest of the field? Curr. Opin. Neurol., 25, 609-613.
13. Rau, F., Freyermuth, F., Fugier, C., Villemin, J.P., Fischer, M.C., Jost, B., Dembele, D., Gourdon, G., Nicole, A., Duboc, D. et al. (2011) Misregulation of miR-1 processing is associated with heart defects in myotonic dystrophy. Nat. Struct. Mol. Biol., 18, 840-845.
14. Yadava, R.S., Frenzel-McCardell, C.D., Yu, Q., Srinivasan, V., Tucker, A.L., Puymirat, J., Thornton, C.A., Prall, O.W., Harvey, R.P. and Mahadevan, M.S. (2008) RNA toxicity in myotonic muscular dystrophy induces NKX2-5 expression. Nat. Genet., 40, 61-68.
15. Wiley, S.R., Cassiano, L., Lofton, T., Davis-Smith, T., Winkles, J.A., Lindner, V., Liu, H., Daniel, T.O., Smith, C.A. and Fanslow, W.C. (2001) A novel TNF receptor family member binds TWEAK and is implicated in angiogenesis. Immunity, 15, 837-846.
16. Burkly, L.C., Michaelson, J.S., Hahm, K., Jakubowski, A. and Zheng, T.S. (2007) TWEAKing tissue remodeling by a multifunctional cytokine: role of TWEAK/Fn14 pathway in health and disease. Cytokine, 40, 1-16.
17. Chicheportiche, Y., Bourdon, P.R., Xu, H., Hsu, Y.M., Scott, H., Hession, C., Garcia, I. and Browning, J.L. (1997) TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J. Biol. Chem., 272, 32401-32410.
18. Brown, S.A., Cheng, E.,Williams, M.S. and Winkles, J.A. (2013) TWEAK-independent Fn14 self-association and NF-kappaB activation is mediated by the C-terminal region of the Fn14 cytoplasmic domain. PLoS One, 8, e65248.
19. Girgenrath, M.,Weng, S., Kostek, C.A., Browning, B.,Wang, M., Brown, S.A.,Winkles, J.A., Michaelson, J.S., Allaire, N., Schneider, P. et al. (2006) TWEAK, via its receptor Fn14, is a novel regulator of mesenchymal progenitor cells and skeletal muscle regeneration. EMBO J., 25, 5826-5839.
20. Brown, S.A., Richards, C.M., Hanscom, H.N., Feng, S.L. and Winkles, J.A. (2003) The Fn14 cytoplasmic tail binds tumour- necrosis-factor-receptor-associated factors 1, 2, 3 and 5 and mediates nuclear factor-kappaB activation. Biochem. J., 371, 395-403.
21. Kumar, M., Makonchuk, D.Y., Li, H., Mittal, A. and Kumar, A. (2009) TNF-like weak inducer of apoptosis (TWEAK) activates proinflammatory signaling pathways and gene expression through the activation of TGF-beta-activated kinase 1. J. Immunol., 182, 2439-2448.
22. Roos, C.,Wicovsky, A., Muller, N., Salzmann, S., Rosenthal, T., Kalthoff, H., Trauzold, A., Seher, A., Henkler, F., Kneitz, C. et al. (2010) Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway. J. Immunol., 185, 1593-1605.
23. Bhatnagar, S. and Kumar, A. (2012) The TWEAK-Fn14 system: breaking the silence of cytokine-induced skeletal muscle wasting. Curr. Mol. Med., 12, 3-13.
24. Burkly, L.C., Michaelson, J.S. and Zheng, T.S. (2011) TWEAK/ Fn14 pathway: an immunological switch for shaping tissue responses. Immunol. Rev., 244, 99-114.
25. Sanz, A.B., Sanchez-Nino, M.D., Izquierdo, M.C., Jakubowski, A., Justo, P., Blanco-Colio, L.M., Ruiz-Ortega, M., Selgas, R., Egido, J. and Ortiz, A. (2010) TWEAK activates the non-canonical NFkappaB pathway in murine renal tubular cells: modulation of CCL21. PLoS One, 5, e8955.
26. Bakkar, N. and Guttridge, D.C. (2010) NF-kappaB signaling: a tale of two pathways in skeletal myogenesis. Physiol. Rev., 90, 495-511.
27. Shin, J., Tajrishi, M.M., Ogura, Y. and Kumar, A. (2013) Wasting mechanisms in muscular dystrophy. Int. J. Biochem. Cell. Biol., 10, 2266-2279.
28. Leeman, J.R. and Gilmore, T.D. (2008) Alternative splicing in the NF-kappaB signaling pathway. Gene, 423, 97-107.
29. Sato, S., Ogura, Y. and Kumar, A. (2014) TWEAK/Fn14 signaling axis mediates skeletal muscle atrophy and metabolic dysfunction. Front. Immunol., 5, 18.
30. Ogura, Y., Mishra, V., Hindi, S.M., Kuang, S. and Kumar, A. (2013) Proinflammatory cytokine tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) suppresses satellite cell self-renewal through inversely modulating Notch and NF-kappaB signaling pathways. J. Biol. Chem., 288, 35159-35169.
31. Gladman, J.T., Yadava, R.S., Mandal, M., Yu, Q., Kim, Y.K. and Mahadevan, M.S. (2015) NKX2-5, a modifier of skeletal muscle pathology due to RNA toxicity. Hum. Mol. Genet., 24, 251-264.
32. Bentzinger, C.F.,Wang, Y.X., Dumont, N.A. and Rudnicki, M.A. (2013) Cellular dynamics in the muscle satellite cell niche. EMBO Rep., 14, 1062-1072.
33. Michaelson, J.S.,Wisniacki, N., Burkly, L.C. and Putterman, C. (2012) Role of TWEAK in lupus nephritis: a bench-to-bedside review. J. Autoimmun., 39, 130-142.
34. Winkles, J.A. (2008) The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat. Rev. Drug. Discov., 7, 411-425.
35. Ren, M.Y. and Sui, S.J. (2012) The role of TWEAK/Fn14 in cardiac remodeling. Mol. Biol. Rep., 39, 9971-9977.
36. Morosetti, R., Gliubizzi, C., Sancricca, C., Broccolini, A., Gidaro, T., Lucchini, M. and Mirabella, M. (2012) TWEAK in inclusion-body myositis muscle: possible pathogenic role of a cytokine inhibiting myogenesis. Am. J. Pathol., 180, 1603-1613.
37. Dogra, C., Changotra, H., Wedhas, N., Qin, X., Wergedal, J.E. and Kumar, A. (2007) TNF-related weak inducer of apoptosis (TWEAK) is a potent skeletal muscle-wasting cytokine. FASEB J., 21, 1857-1869.
38. Mittal, A., Bhatnagar, S., Kumar, A., Lach-Trifilieff, E., Wauters, S., Li, H., Makonchuk, D.Y., Glass, D.J. and Kumar, A. (2010) The TWEAK-Fn14 system is a critical regulator of denervation- induced skeletal muscle atrophy in mice. J. Cell. Biol., 188, 833-849.
39. Mittal, A., Bhatnagar, S., Kumar, A., Paul, P.K., Kuang, S. and Kumar, A. (2010) Genetic ablation ofTWEAKaugments regeneration and post-injury growth of skeletal muscle in mice. Am. J. Pathol., 177, 1732-1742.
40. Hindi, S.M., Mishra, V., Bhatnagar, S., Tajrishi, M.M., Ogura, Y., Yan, Z., Burkly, L.C., Zheng, T.S. and Kumar, A. (2014) Regulatory circuitry of TWEAK-Fn14 system and PGC-1alpha in skeletal muscle atrophy program. FASEB J., 28, 1398-1411.
41. De Palma, C., Morisi, F., Cheli, S., Pambianco, S., Cappello, V., Vezzoli, M., Rovere-Querini, P., Moggio, M., Ripolone, M., Francolini, M. et al. (2012) Autophagy as a new therapeutic target in Duchenne muscular dystrophy. Cell Death Dis., 3, e418.
42. Hollinger, K., Gardan-Salmon, D., Santana, C., Rice, D., Snella, E. and Selsby, J.T. (2013) Rescue of dystrophic skeletal muscle by PGC-1alpha involves restored expression of dystrophinassociated protein complex components and satellite cell signaling. Am. J. Physiol. Regul. Integr. Comp. Physiol., 305, R13-R23.
43. Selsby, J.T., Morine, K.J., Pendrak, K., Barton, E.R. and Sweeney, H.L. (2012) Rescue of dystrophic skeletal muscle by PGC-1alpha involves a fast to slow fiber type shift in the mdx mouse. PLoS One, 7, e30063.
44. Wisniacki, N., Amaravadi, L., Galluppi, G.R., Zheng, T.S., Zhang, R., Kong, J. and Burkly, L.C. (2013) Safety, tolerability, pharmacokinetics, and pharmacodynamics of anti-TWEAK monoclonal antibody in patients with rheumatoid arthritis. Clin. Ther., 35, 1137-1149.
45. Campbell, S., Burkly, L.C., Gao, H.X., Berman, J.W., Su, L., Browning, B., Zheng, T., Schiffer, L., Michaelson, J.S. and Putterman, C. (2006) Proinflammatory effects of TWEAK/Fn14 interactions in glomerular mesangial cells. J. Immunol., 176, 1889-1898.
46. Gladman, J.T., Mandal, M., Srinivasan, V. and Mahadevan, M. S. (2013) Age of onset of RNA toxicity influences phenotypic severity: evidence from an inducible mouse model of myotonic dystrophy (DM1). PLoS One, 8, e72907.
47. Kim, Y.K., Mandal, M., Yadava, R.S., Paillard, L. and Mahadevan, M.S. (2014) Evaluating the effects of CELF1 deficiency in a mouse model of RNA toxicity. Hum. Mol. Genet., 23, 293-302.